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Background:Acute pain is common following surgery, with opioids frequently employed in
its management. Studies indicate that commencing an opioid during a hospital admission
increases the likelihood of long-term use. This study aimed to identify the prevalence of opioid
persistence amongst opioid-naïve patients following surgery as well as the indication for use.
Methods:A retrospective review of patients who underwent a surgical procedure at the
Royal Hobart Hospital, Tasmania, Australia, between August and September 2016 was
undertaken. Patients were linked to the Tasmanian real-time prescription monitoring database
to ascertain if they were subsequently dispensed a Schedule 8 opioid (morphine, codeine
oxycodone, buprenorphine, hydromorphone, fentanyl, methadone, or tapentadol) and the
indication for use.
Results: Of the 3275 hospital admissions, 1015 opioid-naïve patients were eligible for
inclusion. Schedule 8 opioids were dispensed at or within 2 days of discharge in 41.7% of
admissions. Thirty-nine (3.9%) patients received prescribed opioids 2-months post-
discharge; 1.8% of the patients were approved by State Health to be prescribed Schedule 8
opioids regularly for a chronic condition at 6 months, and 1.3% received infrequent or one-
off prescriptions for Schedule 8 opioids at 6 months. Thirteen (1.3%) patients continued
Schedule 8 opioids for at least 6 months following their surgery, with the indication for
treatment either related to the surgery or the condition which surgery was sought for.
Conclusion:This study found that there was a low rate of Schedule 8 opioid persistence
following surgery, indicating post-surgical pain is not a significant driver for persistent opioid
use.
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Background
Acute pain is common and expected following a surgical procedure.1,2 Opioids are
frequently supplied following surgery to manage pain and patients are often dis-
charged home with opioids intended for short-term use to assist with their acute
post-surgical pain management.3 One Australia study found that 82% of the patients
who underwent orthopaedic surgery or neurosurgery were discharged on an opioid.4
International studies report post-surgical opioid dispensing rates vary from 7.1%5 to
80.0%.6
Poor acute pain management increases the risk of post-operative complications,
length of hospital admission, likelihood of readmission7–10 as well as the risk of
persistent post-surgical pain.7 In line with the growing awareness of the importance
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of acute pain management, it has been reported that
between 2004 and 2012, there have been increases in
both the proportion of low-risk surgical patients receiving
an opioid and the mean opioid dose prescribed.6 The rate
of opioid persistence following short-stay surgery, which
is generally considered to result in minimal long-term
pain, was 10% at 1 year, and those prescribed an opioid
post-operatively were more likely to still be taking an
opioid at 12 months.5 Merely receiving an opioid on
hospital discharge, irrespective of surgery, has been asso-
ciated with an increased the likelihood of chronic opioid
use in previously opioid-naïve patients.5,11-14 These stu-
dies did not ascertain the cause or source of pain for which
the opioid was prescribed following discharge.
There has been increasing concern about long-term
opioid use, due to the risk of adverse events and accidental
death.15 To date, two studies16,17 have reviewed post-surgical
opioid persistence in Australia; one in a subset of Australians
(Veterans) which found a persistence rate of 3.1% at 90
days16 and the other study reviewing patients undergoing
elective surgery at a private hospital, which found
a persistence rate of 10.5% at 90 days. However, these
studies were unable to ascertain the cause or source of pain
for long-term opioids. Consequently, this study aims to pro-
vide further detailed information about the prevalence of
opioid use for pain related to surgery or the condition for
which surgery sought, and thus inform clinical practice.
Methods
A retrospective cohort study of patients discharged from
the Royal Hobart Hospital (RHH), Tasmania, Australia
following a surgical procedure was undertaken. All eligi-
ble patients who were discharged from a surgical unit at
the RHH between 1 August and 30 September 2016 were
included in the study.
In Tasmania, all Schedule 8 opioid (morphine, codeine,
oxycodone, buprenorphine, hydromorphone, fentanyl,
methadone, or tapentadol) dispensed by hospital and com-
munity pharmacies is recorded through a real-time prescrip-
tion monitoring system, called Drugs and Poisons
Information System (DAPIS). Inpatient provision of opioids
is not recorded in DAPIS. This system is administered by the
Tasmanian Department of Health and is used to monitor and
authorise prescribing and dispensing of Schedule 8 medica-
tion (and as of February 2018 Schedule 4 opioids, ie, trama-
dol and combination codeine products). If a patient is
supplied a Schedule 8 opioid regularly for a prescribed period
(usually exceeding 2 months), a legal authority is required
from the Department of Health.18 Regular opioid use for
more than 2 months without a legal authority is flagged by
DAPIS and the Department of Health sends the prescriber an
urgent reminder that an authority application is required
immediately. The approval application includes the opioid,
strength, daily dose, and source or cause of pain that requires
an opioid to be prescribed.
Eligible inpatients were identified through discharge
lists (which included patient demographics, the operation
performed and presenting complaint) from all surgical
units at the RHH. Every patient was reviewed using the
digital medical record (DMR) to exclude paediatric
patients, patients that did not undergo surgery or did not
undergo an eligible procedure. Ophthalmic and dental
procedures were excluded. Additionally, diagnostic proce-
dures such as endoscopy, cystoscopy, colposcopy, colono-
scopy, large loop excision of the transformation zone
(LLETZ), prostate biopsy, as well as other less invasive
producers such as dilation and curettage, vasectomy,
angiograms, and procedures that required only local anaes-
thetics were also excluded. Surgical procedures that were
outsourced to one of the local private hospitals were also
excluded from the analysis. Patients prescribed pre-
operative long-term Schedule 8 opioids (defined as having
an authority approved or pending with the Tasmanian
Department of Health, at the time of the surgery and
having had at least one dispensing for an opioid in the 2
months preceding their surgery) were also excluded.
The DAPIS records of eligible patients were then
reviewed. This identified if they had been discharged from
hospital with, or were dispensed a prescription for,
a Schedule 8 opioid within 2 days of their discharge. We
also identified dispensing of opioids at two subsequent time
points; the first 2 months after discharge (this is the time
point used by the Poisons Act 1971 to define chronic opioid
use), the second approximately 6 months after discharge.
Because the daily dose is not recorded on DAPIS for dispen-
sing events (only when authorities are received), assessment
of a supply at 2 and 6 months was undertaken by reviewing
prescriptions dispensed within 2 weeks of the date of interest,
and using standard dosing it was estimated if the patient was
likely to be still taking this medication. In addition, for those
who were receiving an opioid at 6 months, their records were
further reviewed to identify the indication for use and
whether an authority for long term prescribing had been
issued. The daily oral morphine equivalent (MEQ/d) was
calculated for patients with an approval for an opioid.19
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Analysis was performed using SPSS version 24 for
Windows (SPSS Inc., Chicago, IL, USA). Results were
described using medians and interquartile ranges (IQR).
Univariate analysis was undertaken using Chi-square and
Mann–Whitney U-tests. A p-value of <0.05 was considered
statistically significant. Patients who had more than one
admission were only included once in the long-term follow-
up. This study was approved by the Tasmanian Health and
Medical Human Research Ethics Committee (HREC),
Reference No: H0015744, and a consent waiver was granted
by the HREC. This was due to the data being retrospective,
creating impracticalities with contacting potential participates
to gain consent. Additionally, participants were unaware of
their participation and there was no risk to the patient or
changes in treatment due to this study. All data once linked
was deidentified to ensure patient confidentiality was main-
tained. This study was compliant with the Declaration of
Helsinki.
Results
Figure 1 provides information about the flow of patients
through the study. Therewere 3275 surgical admissions during
the research time frame, of which 1015 admissions for 1004
patients were considered eligible. Of the 11 patients who had
multiple admissions, all except one were related to the initial
operation or diagnosis. Four of these patients were prescribed
opioids at discharge, and only one had a prescription dispensed
for a Schedule 8 opioid at 2 months which was provided on
discharge from hospital for a subsequent surgical procedure.
The median age was 47 years (IQR: 31–63 years), and 51.1%
of the cohort were female. There were 419 admissions
(41.7%) that resulted in a patient being discharged with or
receiving a prescription for a Schedule 8 opioid within 2 days
of discharge. Patients who received an opioid were slightly
younger than those who did not (45 years (IQR 31–60 years)
vs 49 (IQR 31–63 years) p =0.02), and there was no significant
difference between the proportion of females and males
receiving opioids (52.6% vs 47.4% p=0.41).
The most commonly supplied Schedule 8 opioid at or
soon after discharge was immediate-release oxycodone,
which was dispensed to 388 patients by itself (92.8%) and
in further 18 patients (4.3%) in combination with a second
Schedule 8 opioid. Other medications dispensed at or in the
immediate 2 days after discharge included modified-release
oxycodone,6 buprenorphine,4 tapentadol,2 morphine,2 and
codeine phosphate.1 It was not possible to record tramadol
Assessed for eligibility
3275 surgical admission
Included
Admissions included: 1015 (31.0%)
(1004 patients)
Opioid at discharge or within 2 days of discharge
419 Patients (41.7%)
Dispensed opioid at 2 months
33 (7.9%)
Dispensed opioid at 6 months
28 (6.7%)
Dispensed opioid at 2 and 6 
months
14 (3.4%)
No opioid at discharge or within 2 days of discharge
596 Patients (59.4%)
Dispensed opioid at 2 months
5 (0.8%)
Dispensed opioid at 6 months
3 (0.5%)
Dispensed opioid at 2 and 6 
months
2 (0.3%)
Excluded
1698 admissions did not have surgery/eligible surgery/surgery was outsourced
17 died in the follow up period
9 admissions had signficiantly extended hospital admissions
102 patients had a history of regular opioids use
434 paediatric patients
Figure 1 Use of opioids by post-surgical patients.
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or combination analgesics containing codeine, as they were
not included in DAPIS at the time of data collection.
The number of dispensings against the mean number of
IR oxycodone tablets (the most commonly prescribed
opioid) provided across all supplies as well as the MEQ
for all Schedule 8 opioids dispensed in the first 2 months
are summarised in Table 1. Most patients (n=317; 75.7%)
received only one supply of an opioid at discharge or
within the following 2 days of discharge; 42 (10.0%) had
two supplies; 21 (5.0%) had three supplies and 34 (8.1%)
had four or more supplies within the first 2 months. Of the
97 patients who were dispensed an opioid on more than
one occasion, 27 (27.8%) had their last prescription dis-
pensed within 7 days of discharge, with a further 20
(20.6%) patients having their last prescription dispensed
within 2 weeks of their discharge.
At approximately 2 months after discharge, 38 (3.8%)
patients had a prescription for a Schedule 8 opioid dis-
pensed. Thirty-three of these patients had received opioids
in the 2 days after discharge. At 6 months, 31 (3.1%)
patients were dispensed a prescription for a Schedule 8
opioid. Thirteen were dispensed infrequent or one-off
Schedule 8 opioid prescription, while 18 patients were
dispensed regular Schedule 8 opioids and the prescriber
had applied for an authority for continued opioid prescrip-
tion. Of these 18 patients, 16 were also dispensed opioids
at 2 months and 14 patients were dispensed opioids at all
three time points (post-discharge, 2, and 6 months).
Of the 16 patients whowere taking opioids at both 2 and 6
months, 4 were unrelated to surgery or the surgical condition;
and 12 were either related to the condition that required
surgery (n=5) eg, metastatic cancer pain following surgery
to remove cancer, or as a consequence of surgery (n=7) eg,
failed back surgery. For the two applications where the
patient was not taking opioids at 2 months, one was asso-
ciated with the condition for which they sought surgery for
and the other was for an unrelated condition. Three applica-
tions cited multiple indications for the opioids including the
surgery or condition for which surgery was sought and three
authorities were for metastatic cancer associated with their
surgery. The indications for long-term opioid prescribing for
those related to the surgical procedure or condition requiring
surgery are presented in Table 2.
For those patients where the opioid(s) were prescribed
due to the surgery or the surgical condition, the median
MEQ/d was 16 mg (range 5–165 mg MEQ/d). Two patients
were prescribed daily doses exceeding 50 mg MEQ/d.
There were 19 opioids approved for 13 patients, 8 patients
prescribed oxycodone immediate-release tablets, with other
approved opioids including oxycodone/naloxone modified
release,7 buprenorphine patches,1 morphine modified
release capsules,1 methadone tablets,1 and tapentadol mod-
ified-release tablets.1
Discussion
This study indicates that only a small proportion (1.3%) of
patients, who were opioid naïve prior to surgery, were
taking opioids 6 months following their surgical discharge,
with the indication for use either related to the surgery or
the condition for which surgery was sought. With the
exception of two patients with an opioid intake exceeding
50 mg MEQ/d, the majority received only low-moderate
dose opioids (in terms of MEQ/day) potentially indicating
that prescribers are heeding recommendations regarding
the use of the lowest effective dose of opioids.
Although this is the third Australian study that we are
aware of that has reviewed the persistence of opioids in
opioid-naïve patients undergoing a surgical procedure, but
Table 1 The Number of Dispensings Against the Average
Amount of Opioid Prescribed in the First 2 Months Following
Surgery (n=419 Patients)
Mean Number of IR
Oxycodone Tablets
Provided, n (SD)
Average MEQ of All
Opioids Dispensed,
MEQ mg (SD)
1 dispensing
(within two
days of
discharge)
16 (6.0) 130.2 (70.5)
2 dispensings 36 (11.3) 304.8 (174.3)
3 dispensings 58 (34.0) 564.5 (236.2)
4 or more
dispensings
76 (46.0) 923.2 (922.1)
Table 2 Indication for Long-Term Opioid and Type of Surgery
Pain Surgical Category Number of
Patients
Back/neck pain Back/neck surgery 3
Abdominal pain/
bowel cancer
Laparoscopic abdominal
surgery
3
Tumour/metastasis Craniotomy 2
Phantom pain Post toe/leg amputation 2
Non-healing wound
pain
Wound debridement 1
Abdominal pain Laparotomy 1
Chest pain Cardiothoracic surgery 1
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in contrast to previous research, this study determined the
source or site of pain that necessitated long-term prescribing
of Schedule 8 opioids. The persistence rates identified in this
study are lower than both recent Australian studies16,17 and
a number of other international studies.5,6,12,13 However, our
results are consistent with a recent Danish study13 which
found an increase of 1.4% (at 1 year) from baseline.
Potentially, the lower rates of persistence identified in this
study may have been associated with three aspects: 1) our
study was able to determine the reasons for long-term opioids
rather than all cause prescribing; 2) our study was unable to
assess the persistence of Schedule 4 opioids; 3) the surgical
indication in some of the previous studies14 focussed on
surgeries more likely to result in pain, eg, orthopaedic or
neurology.
This study also found that many patients were dis-
pensed Schedule 8 opioids at or immediately following
discharge (41.7% of the surgical admissions) which was
consistent with Clark and colleagues14 who found 49.2%
of the patients were discharged with an opioid. In our
study, over three-quarters of these patients received only
one supply and few received further supplies of opioids
beyond 2 weeks after their discharge. This is consistent
with the study conducted by Roughead and colleagues,
which reported that 70% of the patients had ceased opioids
by 14 days.16 Additionally, the quantity of medication
supplied for patients receiving only one post-discharge
prescription of Schedule 8 opioids, was on average less
than a standard box (quantity 20) of immediate-release
oxycodone, indicating that prescribers were not providing
excessive quantities of opioids in each prescription.
Our finding of expedient cessation of opioids, as well
as the low rates of persistence, suggests that opioids dis-
pensed following surgery are not a major contributor to
long-term opioid prescribing. However, this study was
unable to determine the utilisation of tramadol or combi-
nation analgesics containing codeine following hospital
discharge and this is likely to result in an underestimate
of the likelihood of opioid persistence, with a previous
study identifying patients commenced on tramadol follow-
ing surgery were as likely, if not more likely to persistent
taking opioids long term.20
There are some limitations with this study, including the
use of only one site (albeit the largest hospital in Tasmania)
and a short (2 months) recruitment period. Two months
were selected as one of the follow-up time points to be
reviewed because the Poisons Act 1971 defines this as the
time when opioid use becomes chronic. However, it is noted
that other studies have reviewed use up to 90 days to one
post-operative year21 which may make comparison of per-
sistent rates between studies difficult. Further research
should be undertaken to determine the long-term use of
other opioids, namely tramadol and codeine combination
products following surgery to complement this study.
Conclusion
This study found there was a low rate of Schedule 8 opioid
persistence following surgery. Only 1.3% of opioid-naïve
patients were prescribed Schedule 8 opioids for at least 6
months following their surgery, with the indication for
treatment either related to the surgery or the condition
which surgery was sought for. To complete the picture
further research is needed to identify the prevalence and
persistence of tramadol and codeine containing analgesic
use following surgery.
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